Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: A putative mechanism

American Journal of Physiology - Cell Physiology

Volumn 296, Issue 1, 2009, Pages

  Zheng, Xin ^a   Chu, Fei ^a   Chou, Pauline M ^a   Gallati, Christine ^c   Dier, Usawadee ^c   Mirkin, Bernard L ^a,b   Mousa, Shaker A ^c   Rebbaa, Abdelhadi ^c  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Drug resistance; Estrogen receptor; Histone deacetylase 1; Topoisomerase

Indexed keywords

ANDROGEN RECEPTOR; BCR ABL PROTEIN; CATHEPSIN L; CATHEPSIN L INHIBITOR; CISPLATIN; CYSTEINE PROTEINASE INHIBITOR; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE ALPHA ATP HYDROLYSING; DOXORUBICIN; ESTROGEN RECEPTOR ALPHA; ETOPOSIDE; FLUTAMIDE; HISTONE DEACETYLASE 1; IMATINIB; TAMOXIFEN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG ACCUMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG STABILITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEINASE INHIBITION; TOXICITY TESTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHEPSINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICE, NUDE; NEUROBLASTOMA; OSTEOSARCOMA; P-GLYCOPROTEIN; PROTEIN STABILITY; PROTEIN TRANSPORT; TIME FACTORS;

MUS MUSCULUS;

EID: 58349113405     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00082.2008     Document Type: Article

References (37)

1. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 64: 7706-7710, 2004.
2. Beck WT, Danks MK, Wolverton JS, Granzen B, Chen M, Schmidt CA, Bugg BY, Friche E, Suttle DP. Altered DNA topoisomerase II in multidrug resistance. Cytotechnology 11: 115-119, 1993.
3. Biedler JL. Drug resistance: genotype versus phenotype-thirty- second G. H. A. Clowes Memorial Award Lecture. Cancer Res 54: 666-678, 1994.
4. Bocock JP, Edgell CJ, Marr HS, Erickson AH. Human proteoglycan testican-1 inhibits the lysosomal cysteine protease cathepsin L. Eur J Biochem 70: 4008-4015, 2003.
5. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9: 1050-1058, 1991.
6. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6: 1075-1085, 2006.
7. Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT, Olsen BR. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci USA 99: 7883-7888, 2002.
8. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19: 341-346, 2007.
9. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20: 543-556, 2006.
10. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880, 2001.
11. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 29: 607-649, 1995.
12. Goulet B, Baruch A, Moon NS, Poirier M, Sansregret LL, Erickson A, Bogyo M, Nepveu A. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell 14: 207-219, 2004.
13. Jarvinen TA, Liu ET. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 6: 579-602, 2006.
14. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5: 443-453, 2004.
15. Kane SE, Gottesman MM. The role of cathepsin L in malignant transformation. Semin Cancer Biol 1: 127-136, 1990.
16. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99: 112-128, 2007.
17. Maehr R, Mintern JD, Herman AE, Lennon-Dumenil AM, Mathis D, Benoist C, Ploegh HL. Cathepsin L is essential for onset of autoimmune diabetes in NOD mice. J Clin Invest 115: 2934-2943, 2005.
18. Mehta K, Devarajan E, Chen J, Multani A, Pathak S. Multidrug-resistant MCF-7 cells: an identity crisis? J Natl Cancer Inst 94: 1652-1654, author reply 1654, 2002.
19. Mirkin BL, Clark S, Zheng X, Chu F, White BD, Greene M, Rebbaa A. Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 24: 4965-4974, 2005.
20. Moscow JA, Cowan KH. Multidrug resistance. J Natl Cancer Inst 80: 14-20, 1988.
21. Nitschke R, Starling K, Lui VK, Pullen J. Doxorubicin and cisplatin therapy in children with neuroblastoma resistant to conventional therapy: a Southwest Oncology Group Study. Cancer Treat Rep 65: 1105-1108, 1981.
22. Osborne CK. Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 47: 83-89, 1993.
23. Rebbaa A, Chou PM, Mirkin BL. Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol Med 7: 393-400, 2001.
24. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11: 643-658, 2004.
25. Rousselet N, Mills L, Jean D, Tellez C, Bar-Eli M, Frade R. Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res 64: 146-151, 2004.
26. Sahagian GG, Gottesman MM. The predominant secreted protein of transformed murine fibroblasts carries the lysosomal mannose 6-phosphate recognition marker. J Biol Chem 257: 11145-11150, 1982.
27. Sever S, Altintas MM, Nankoe SR, Moller CC, Ko D, Wei C, Henderson J, del Re EC, Hsing L, Erickson A, Cohen CD, Kretzler M, Kerjaschki D, Rudensky A, Nikolic B, Reiser J. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 117: 2095-2104, 2007.
28. Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell 2: 99-102, 2002.
29. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 102: 11876-11881, 2005.
30. Stypmann J, Glaser K, Roth W, Tobin DJ, Petermann I, Matthias R, Monnig G, Haverkamp W, Breithardt G, Schmahl W, Peters C, Reinheckel T. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA 99: 6234-6239, 2002.
31. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Nilsson J, Bergh J. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24: 2428-2436, 2006.
32. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159-165, 2003.
33. Tobin DJ, Foitzik K, Reinheckel T, Mecklenburg L, Botchkarev VA, Peters C, Paus R. The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am J Pathol 160: 1807-1821, 2002.
34. Troen BR, Ascherman D, Atlas D, Gottesman MM. Cloning and expression of the gene for the major excreted protein of transformed mouse fibroblasts. A secreted lysosomal protease regulated by transformation. J Biol Chem 263: 254-261, 1988.
35. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108: 1328-1333, 2006.
36. Wright WW, Smith L, Kerr C, Charron M. Mice that express enzymatically inactive cathepsin L exhibit abnormal spermatogenesis. Biol Reprod 68: 680-687, 2003.
37. Zheng X, Chou PM, Mirkin BL, Rebbaa A. Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Cancer Res 64: 1773-1780, 2004.